Screener
Axsome Therapeutics AXSM Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebt.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Net cash used in investing activities | (121) | (338) |
| Cash flows from financing activities | ||
| Proceeds from draw down of debt | 70,000 | — |
| Repayment of debt | (70,000) | — |
| Payments on principal portion of finance lease obligation | (672) | (401) |
| Proceeds from issuance of common stock upon financing | 6,343 | 19,650 |
| Cash paid for common stock issuance costs | (95) | (393) |
| Proceeds from issuance of common stock upon exercise of options | 9,981 | 17,035 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's debt repayments?
- Axsome Therapeutics (AXSM) reported debt repayments of $70M in Q1 2026.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about Axsome Therapeutics's debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude